User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Uncommon EGFR mutations on osimertinib, real-life data (UNICORN study): Updated results, brain efficacy, and resistance mechanisms.

Primary tabs

download
  • Open access
  • PDF
  • 54.27 K
Bar, Jair Peled, Nir Schokrpur, Shiruyeh Dudnik, Elizabeth Wollner, Mira Aboubakar Nana, Frank [UCL] Addeo, Alfredo

BACKGROUND : About 10% of EGFR mutations (EGFRm) are ‘uncommon mutations’ (ucEGFRm). osimertinib is a 3rd generation EGFRi, active against common EGFRm. We aimed to collect real-world data about systemic and brain response and resistance mechanisms to osimertinib for ucEGFRm patients.

Document type Communication à un colloque (Conference Paper) – Présentation orale avec comité de sélection, Abstract
Access type Accès libre
Publication date 2022
Language Anglais
Conference "2022 ASCO Annual Meeting", (United States) Chicago, IL (du 03/06/2022 au 07/06/2022)
Journal information "Journal of Clinical Oncology" - Vol. 40, no.Suppl 16, p. 9109 (2022)
Peer reviewed yes
issn 0732-183X
e-issn 1527-7755
Publisher American Society of Clinical Oncology (ASCO) ((United States) Alexandria, VA)
Publication status Publié
Affiliations UCL - SSS/DDUV/GECE - Génétique cellulaire
UCL - SSS/IREC/LUNS - Pôle pneumologie, ORL (airways) et dermatologie (skin)
UCL - (SLuc) Service de pneumologie
Keywords Cancer Research ; Oncology
Links
Bibliographic reference Bar, Jair ; Peled, Nir ; Schokrpur, Shiruyeh ; Dudnik, Elizabeth ; Wollner, Mira ; et. al. Uncommon EGFR mutations on osimertinib, real-life data (UNICORN study): Updated results, brain efficacy, and resistance mechanisms..2022 ASCO Annual Meeting ((United States) Chicago, IL, du 03/06/2022 au 07/06/2022). In: Journal of Clinical Oncology, Vol. 40, no.Suppl 16, p. 9109 (2022)
Permanent URL http://hdl.handle.net/2078.1/268032